Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 4

Crinetics Pharmaceuticals, Inc.

SEC Filing

Filed Sep 1, 2026Accepted Sep 1, 2026, 4:55 PM EDTCIK 1658247Accession 0001628280-26-059885
Share

Company context

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

Historical securities (1)

Recent company filings

  1. 15-12G filingSep 11, 2026
  2. 4 filingSep 1, 2026
  3. 4 filingSep 1, 2026
  4. 4 filingSep 1, 2026
  5. 4 filingSep 1, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗